Immuno-virological and Clinical Follow-up of Persons With HIV-2 (PWHIV-2) Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate (BIC/FTC/TAF): A Retrospective Study
This retrospective study evaluated Bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) in 24 persons with human immunodeficiency virus type 2 (HIV-2, PWHIV-2), 5 naive and 19 pretreated. After a median follow-up of 37.5 months, all PWHIV-2 had a plasma viral load <40 copies/mL. Median CD4 count increased significantly from 580 to 625 cells/mm3, suggesting the effectiveness of BIC/FTC/TAF to treat HIV-2 infection.
Authors
- Véronique Joly (ORCID: https://orcid.org/0000-0002-2005-102X)
- Sophie Matheron
- Valentine Marie Ferré (ORCID: https://orcid.org/0000-0002-2196-6141)
- Jade Ghosn (ORCID: https://orcid.org/0000-0003-2914-959X)
- Quentin Le Hingrat (ORCID: https://orcid.org/0000-0001-9017-4941)
- Diane Descamps (ORCID: https://orcid.org/0000-0002-6556-1525)
- M Digumber
- Mélanie Cresta
- Charlotte Charpentier (ORCID: https://orcid.org/0000-0002-6441-7054)
- Gilles Peytavin (ORCID: https://orcid.org/0000-0002-4359-537X)
- Florence Damond
- Yazdan Yazdanpanah
Institutions
- Inserm (FR)
- Délégation Paris 7 (FR)
- Université Paris Cité (FR)
- Sorbonne Paris Cité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Bichat-Claude-Bernard (FR)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1093/cid/ciae447
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00